The Economic Times
English EditionEnglish Editionहिन्दी
| 28 February, 2021, 05:28 PM IST | E-Paper

    Scientists sceptical about Russia's Covid vaccine, cite lack of evidence for efficacy

    While the country hopes to start mass-producing the vaccine by October and plans to offer the first doses to essential workers, many in the science community seem unimpressed. The announcement should be taken "with a pinch of salt", said Indian immunologist Vineeta Bal.

    Data breach prompts Dr Reddy's to shut key plants

    Pharma major Dr. Reddy's Laboratories shut down its production facilities following a data breach in the servers, ET Now reported, citing sources.Data breach prompts Dr Reddy's to shut key plants

    Days after Russian COVID-19 vaccine trial approval, data breach forces Dr Reddy's plants shut

    In September 2020, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.

    Russia expected to register second COVID-19 vaccine on Oct 15: Developer

    The vaccine has been developed by Siberia's Vector Institute, which completed early-stage human trials of the vaccine last month.

    India declines proposal to test Sputnik-V Covid vaccine in large study

    India's move comes as a setback for Russia's plan to roll-out the vaccine even before full trials show how well it works, while pushing back its efforts to win approval for the vaccine in the country that leads the world on average number of new infections.

    Here’s why Russia wants to produce the coronavirus vaccine in India

    Early in August, the Russians announced that they had successfully created a vaccine against the coronavirus, even as competitors remained in trial stages, with no products expected till 2021.

    The Economic Times